Transcriptional activation of NF-κB activity by Epstein-Barr virus (EBV) LMP1 as a selective therapeutic strategy for EBV-associated diseases

Gene Therapy

Volumn 5, Issue 7, 1998, Pages 905-912

  Wu, C J ^a   Leu, C Y ^b   Liu, S T ^b   Chow, K P ^b   Meng, C L ^a   Chang, Y S ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

EBV LMP1; Ganciclovir; Gene therapy; NF B activation; Suicide gene; Thymidine kinase

Indexed keywords

GANCICLOVIR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOPROTEIN; THYMIDINE KINASE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANTIBIOTIC SENSITIVITY; ARTICLE; EPSTEIN BARR VIRUS; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INTRAPERITONEAL DRUG ADMINISTRATION; LONG TERMINAL REPEAT; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RECOMBINANT GENE; SUICIDE GENE; TRANSCRIPTION REGULATION; TUMOR REGRESSION; VIRUS CARCINOGENESIS;

ANIMALIA; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 0031827297     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300688     Document Type: Article

References (33)

1. Hsu MM, Tu SM. Nasopharyngeal cancer in Taiwan. Cancer 1983; 52: 362-368.
2. Fahraeus R et al Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988; 42: 329-338.
3. Lupton S, Levine AJ. Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of EpsteinBarr virus-derived plasmids in human cells. Mol Cell Biol 1985; 5: 2533-2542
4. Chen ML et al. Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogens 1992; 7: 2131-2140.
5. Hammarskjold ML, Simurda MC. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kB activity. J Virol 1992; 66: 6496-6501.
6. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP-1) mediates activation of NF-KB and cell surface phenotype via two effector regions in its carboxy terminal cytoplasmic domain. Oncogene 1995; 10: 549-560.
7. Paine E, Scheinman RI, Baldwin-As JR, Raab-Traub N. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-κB/Rel family proteins. J Virol 1995; 69: 4572-4576.
8. Herrero JA, Mathew P, Paya CV. LMP-1 activates NF-κB by targeting the inhibitory molecule IκBα. J Virol 1995; 69: 2168-2174.
9. Freeman SM et al. The 'bystander effect : tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274 - 5283.
10. Osaki T et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 1994; 54: 5258-5261.
11. Ring CJA, Harris JD, Hurst HC, Lemoine NR. Suicide gene expression induced in tumor cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Therapy 1996; 3: 1094-1103.
12. Obaru K et al. Gene therapy for adult T cell leukemia using human immunodeficiency virus vector carrying the thymidine kinase gene of herpes simplex virus type 1. Hum Gene Ther 1996; 7: 2203-2208.
13. Culver KW et al. In vitro gene transfer with retroviral vectorproducer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
14. Barba D, Hardin J, Sadelain M, Gate FH. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 4348-4352.
15. Kumagai T et al. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements. Cancer Res 1996; 56: 354-358.
16. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
17. Paul S, Dummer S. Topics in clinical pharmacology: ganciclovir. Am J Med Sci 1992; 304: 272-277.
18. Huber BE, Richards CA, Krenitsky TA. Retrovirus-mediated gene therapy for the treatment of hepatocellular carcinoma, an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991; 88: 8039-8043.
19. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993; 53: 3860-3864.
20. Judde JG, Spangler G, Magrath I, Bhatia K. Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia. Hum Gene Ther 1996; 7: 647-653.
21. Evans TJ, Brooks L, Farrell P. A strategy for specific targeting of therapeutic agents to tumor cells of virus-associated cancers. Gene Therapy 1997; 4: 264-267.
22. Rogers RP et al. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase. Hum Gene Ther 1997; 7: 2235-2245.
23. Herbst H et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 1991; 88: 4766-4770.
24. Lones MA et al Post-transplant lymphoproliferative disorder in liver allograft biopsies: a comparison of three methods for the demonstration of Epstein-Barr virus. Hum Pathol 1997; 28: 533-539.
25. Chen CL et al. Epstein-Barr virus (EBV) gene expression in EBVpositive peripheral T cell lymphomas. J Virol 1993; 67: 6303-6308.
26. Chang YS et al. Detection of an Epstein-Barr virus variant in T cell lymphoma tissues identical to the distinct strain observed in nasopharyngeal carcinoma in the Taiwanese population. Int J Cancer 1995; 62: 673-677.
27. Knecht H et al. Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene 1995; 10: 523-528.
28. Yeh TS et al. Sequence variations between two Epstein-Barr virus LMP1 variants have no effect on the activation of NF-KB activity. DNA Cell Biol 1997; 16: 1311-1319.
29. Rothenberger S et al. Natural 30 base pair and 69 base pair deletion variants of the LMP1 oncogene do stimulate NF-κBmediated transcription. Oncogene 1997; 14: 2123-2126.
30. Tsai CN, Liu ST, Chang YS. Identification of a novel promoter located within the BamHI Q region of the Epstein-Barr virus genome for the EBNA1 gene. DNA Cell Biol 1995; 14: 767-776.
31. Chang MS et al. Identification of a promoter for latent membrane protein 1 gene of Epstein-Barr virus that is specifically activated in human epithelial cells. DNA Cell Biol 1997; 7: 829-837.
32. Golumbek PTet al. Herpes simplex virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother 1992; 12: 224-230.
33. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-467.